title: Effects of tibolone on osteoarthritis in ovariectomized rats: association with nociceptive pain behaviour.
abstract: BACKGROUND
  To investigate the role of the synthetic steroid tibolone in the progression of osteoarthritis (OA) and in nociceptive behaviour in an experimental rat model of OA and ovariectomy (OVX)-induced osteoporosis.
  
  
  METHODS
  OA was induced in Wistar rats by anterior cruciate ligament transection (ACLT) of the right knee. Osteoporosis was induced by bilateral OVX. Groups of animals were subjected to ACLT, OVX, sham or OVX + ACLT. In addition, two groups were subjected to OVX + ACLT surgeries and were orally administered 0.1 or 0.5 mg tibolone every other day for 14 consecutive weeks, starting 6 weeks after surgery. Nociceptive behaviours (secondary mechanical allodynia and weight-bearing distribution of the hind paws) were analysed prior to and every 3 weeks after surgery up to 24 weeks. At 24 weeks, histopathological studies were performed on the cartilage and synovial membranes of the knee joints, and bone metabolism was assessed by measuring serum concentrations of calcium, phosphorus and alkaline phosphatase.
  
  
  RESULTS
  Rats undergoing ACLT or OVX + ACLT surgeries showed obvious OA changes in the joints. Animals subjected to ACLT + OVX and treated with tibolone had significantly less cartilage degeneration and synovitis and showed improved nociceptive tests compared with animals undergoing ACLT + OVX surgeries alone. OVX increased the severity of the ACLT-induced OA changes. There was a significant increase in serum alkaline phosphatase in the tibolone-treated ACLT + OVX groups.
  
  
  CONCLUSIONS
  Treatment with tibolone attenuated the development of OA, concomitantly reduced nociception and increased serum alkaline phosphatase in ACLT + OVX rats.
authors.affiliation: Department of Obstetrics and Gynecoloy, Changhua Christian Hospital, Pingtung, Taiwan.
authors.forename: P-Y
authors.initials: PY
authors.lastname: Yang
authors.forename: C-C
authors.initials: CC
authors.lastname: Tang
authors.forename: Y-C
authors.initials: YC
authors.lastname: Chang
authors.forename: S-Y
authors.initials: SY
authors.lastname: Huang
authors.forename: S-P
authors.initials: SP
authors.lastname: Hsieh
authors.forename: S-S
authors.initials: SS
authors.lastname: Fan
authors.forename: H-P
authors.initials: HP
authors.lastname: Lee
authors.forename: S-C
authors.initials: SC
authors.lastname: Lin
authors.forename: W-F
authors.initials: WF
authors.lastname: Chen
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Wen
authors.forename: Y-H
authors.initials: YH
authors.lastname: Jean
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D000070598:Anterior Cruciate Ligament Injuries; D001522:Behavior, Animal / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D005260:Female; D007596:Joints / Q000473:pathology; D059226:Nociceptive Pain / Q000188:drug therapy* / Q000523:psychology*; D009652:Norpregnenes / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy* / Q000473:pathology; D010052:Ovariectomy; D051381:Rats; D017208:Rats, Wistar; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016474:Weight-Bearing
chemical_list: D000700:Analgesics; D009652:Norpregnenes; D020845:Selective Estrogen Receptor Modulators; C027385:tibolone